Shuang Liu, PhD, Founder & CEO Co-inventor of CSTI-500. 20 years of experience in drug R&D as an integrated project leader. Led AMRI’s triple monoamine program that delivered 4 NCEs, including CSTI-500, for clinical development. Led other successful discovery programs in CNS, oncology, and autoimmune at AMRI. Co-Inventor of >30 patent families. PhD in organic chemistry from the University of Georgia with postdoc training at Emory University.
John Maki, Acting President 30 years of management and investment experience in life science. Formerly CEO of Vicus Therapeutics a clinical-stage immuno-oncology company, Managing Director at TDI and Audax Group, Principal at Bain Capital and Consultant at Bain & Company. Mr. Maki serves on the boards of Vicus Therapeutics and 3DMatrix as well as the Board of Trustees of BIO NJ. AB in Economics from Harvard University.
Roman Dvorak, MD, PhD, Chief Medical Officer Over 25 years of clinical development, global regulatory leadership, and business development experience. Former CMO at Saniona where he led PWS and HO clinical trials of Tesomet. Also involved with Qnexa® & Meridia® clinical studies whilst holding senior roles at Vivus and Knoll, respectively. Roman has held other senior roles with Pfizer and J&J amongst others, and has specialist expertise in endocrinology & metabolic disorders.
Lois Rosenberger, PhD, Head of Regulatory President of LBR Regulatory and Clinical Consulting Services. 30+ years of regulatory, quality assurance, and 20+ years of experience in managing clinical trials including for PWS. Lois held regulatory leadership positions at Kendle CRO, Marion-Merrell Dow, and P&G.
Allen Ritter, PhD, Contract CMC 30 years of experience in the development, manufacturing, outsource manufacturing, and registration of pharmaceuticals. Former VP Manufacturing/CMC at Endocyte and CMC/QA management positions at Eli Lilly.